System-Specific Biopharmaceuticals

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM)

OPTIMI HEALTH CORP

HCW Biologics

Silexion Therapeutics

Vida Global

GCL Global

BiomX

MetaVia

Micware

MicroAlgo

BFRIW

Earnings Watch

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 10.08 M

Biofrontera AG has announced the pre-announcement of its financial report for the year 2025, covering the period from January 1, 2025, to December 31, 2025. The report will be published on April 17, 2026. The company operates in the regulated markets of Dusseldorf and Frankfurt, as well as in the free markets of Munich, Stuttgart, and Tradegate.

pressetext

Biofrontera AG

Pre-announcement of a financial report according to articles 114 - 117 WpHG

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 10-K: FY2025 Revenue: USD 41.71 M

Biofrontera reports rise in Q4 revenue, turns profitable

businessinsider

First Trust NYSE Arca Biotech Index Fd

Biofrontera reports rise in Q4 revenue, turns profitable

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2025 Q4 Revenue: USD 17.1 M

ARKG

SBIO

BFRI

Biofrontera Sets 2026 Guidance and Highlights Growing U.S. Earn-Out Income

Tip Ranks

iShares Biotechnology ETF

VanEck Biotech ETF

Ark Genomic Revolution ETF

ALPS Medical Breakthrough

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Proshares Ultra Nasdaq Biotech

Biofrontera

Biofrontera Sets 2026 Guidance and Highlights Growing U.S. Earn-Out Income

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM)(BFRIW.US)

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2026 Q1 Revenue: USD 10.08 M

Pre-announcement of a financial report according to articles 114 - 117 WpHG

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 10-K: FY2025 Revenue: USD 41.71 M

Biofrontera reports rise in Q4 revenue, turns profitable

BIOFRONTERA INC C/WTS 27/10/2026 (TO PUR COM) | 8-K: FY2025 Q4 Revenue: USD 17.1 M